Nasdaq welcomes Forward Pharma A/S (Nasdaq: FWP) to The Nasdaq Stock Market

Nasdaq (Nasdaq: NDAQ) announced that trading of Forward Pharma A/S (Nasdaq: FWP) commenced on The Nasdaq Stock Market on October 15, 2014.

Headquartered in Copenhagen, Denmark, Forward Pharma is a biopharmaceutical company focused on a proprietary formulation of an immunomodulatory compound for the treatment of multiple sclerosis and other immune-related diseases such as psoriasis.

“We are excited to welcome Forward Pharma to the growing list of biotech companies that call Nasdaq home,” said Adam Kostyál, Senior Vice President, Nasdaq Listing Services. “Forward Pharma is the first Nordic company to list on Nasdaq via an F1 filing. This enables the company to remain headquartered in Denmark, while reaching investors at The Nasdaq Stock Market.”

”Today, the ADSs of Forward Pharma begin trading on the Nasdaq market.  We are now a publicly traded company and are proud to offer investors the opportunity to take part in Forward Pharma’s future development,” said Florian Schönharting, Chairman of the Board at Forward Pharma.”

By listing with Nasdaq, Forward Pharma joins some of the world’s largest and most revolutionary companies. Nasdaq has been the exchange of choice to 92 percent of healthcare companies that have listed on the U.S. markets year-to-date in 2014.